Nov. 24 at 9:13 AM
$ASRT Neulasta, developed by Amgen, was a top-selling drug for many years, but its sales have eroded significantly since biosimilars entered the market, particularly after 2018.
2023: Global sales were
$848 million.
2022: Full-year sales were
$1.126 billion.
2020: Total sales were
$2.3 billion (with US sales accounting for
$2 billion).
2019: Total sales were approximately
$3.2 billion.
2018: Total sales were
$4.5 billion.
Peak Sales: In 2014, Neulasta generated nearly
$3.6 billion in revenue from July 2013 to July 2014, making it one of the top 10 best-selling drugs at the time.
Factors Affecting Sales
Biosimilar Competition: The introduction of several biosimilar versions (e.g., Fulphila, Udenyca, Ziextenzo, Nyvepria) in the US and global markets has driven prices down and reduced market share for the original Neulasta.
Price Reductions: The selling price for Neulastadropped significantly after biosimilar entry; the average sales price dropped 41% by the second quarter of 2021.
